Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 256

1.

Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma.

Sinik L, Minson KA, Tentler JJ, Carrico J, Bagby SM, Robinson WA, Karni R, Burstyn-Cohen T, Eckhardt SG, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK.

Mol Cancer Ther. 2018 Nov 27. pii: molcanther.0456.2018. doi: 10.1158/1535-7163.MCT-18-0456. [Epub ahead of print]

PMID:
30482852
2.

CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma.

Ravindran Menon D, Luo Y, Arcaroli JJ, Liu S, KrishnanKutty LN, Osborne DG, Li Y, Samson JM, Bagby S, Tan AC, Robinson WA, Messersmith WA, Fujita M.

Cancer Res. 2018 Dec 1;78(23):6561-6574. doi: 10.1158/0008-5472.CAN-18-0330. Epub 2018 Oct 8.

PMID:
30297536
3.

BRAF fusions identified in melanomas have variable treatment responses and phenotypes.

Turner JA, Bemis JGT, Bagby SM, Capasso A, Yacob BW, Chimed TS, Van Gulick R, Lee H, Tobin R, Tentler JJ, Pitts T, McCarter M, Robinson WA, Couts KL.

Oncogene. 2018 Sep 25. doi: 10.1038/s41388-018-0514-7. [Epub ahead of print]

PMID:
30254212
4.

BH3 mimetics induce apoptosis independent of DRP-1 in melanoma.

Mukherjee N, Strosnider A, Vagher B, Lambert KA, Slaven S, Robinson WA, Amato CM, Couts KL, Bemis JGT, Turner JA, Norris DA, Shellman YG.

Cell Death Dis. 2018 Sep 5;9(9):907. doi: 10.1038/s41419-018-0932-z.

5.

Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.

Tobin RP, Jordan KR, Robinson WA, Davis D, Borges VF, Gonzalez R, Lewis KD, McCarter MD.

Int Immunopharmacol. 2018 Oct;63:282-291. doi: 10.1016/j.intimp.2018.08.007. Epub 2018 Aug 16.

6.

The American Orthopaedic Association's Own the Bone® database: a national quality improvement project for the treatment of bone health in fragility fracture patients.

Carlson BC, Robinson WA, Wanderman NR, Nassr AN, Huddleston PM 3rd, Yaszemski MJ, Currier BL, Jeray KJ, Kirk KL, Bunta AD, Murphy S, Patel B, Watkins CM, Sietsema DL, Edwards BJ, Tosi LL, Anderson PA, Freedman BA.

Osteoporos Int. 2018 Sep;29(9):2101-2109. doi: 10.1007/s00198-018-4585-7. Epub 2018 Jun 1.

PMID:
29858634
7.

Retropharyngeal Steroid Use in Anterior Cervical Discectomy and Fusion.

Robinson WA, Carlson BC, Freedman BA, Sebastian AS.

Clin Spine Surg. 2018 May 22. doi: 10.1097/BSD.0000000000000653. [Epub ahead of print] No abstract available.

PMID:
29794533
8.

IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics.

Hintzsche JD, Yoo M, Kim J, Amato CM, Robinson WA, Tan AC.

BMC Med Genomics. 2018 Apr 20;11(Suppl 2):26. doi: 10.1186/s12920-018-0350-1.

9.

Successful treatment of disseminated Rosai-Dorfman disease with siltuximab.

Lee H, King G, Garg K, Pan Z, Tobin J, Robinson WA.

Haematologica. 2018 Jul;103(7):e325-e328. doi: 10.3324/haematol.2018.188441. Epub 2018 Mar 29. No abstract available.

10.

Long-term outcomes of humeral head replacement for the treatment of osteoarthritis; a report of 44 arthroplasties with minimum 10-year follow-up.

Robinson WA, Wagner ER, Cofield RH, Sánchez-Sotelo J, Sperling JW.

J Shoulder Elbow Surg. 2018 May;27(5):846-852. doi: 10.1016/j.jse.2017.10.017. Epub 2017 Dec 18.

PMID:
29269140
11.

ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.

Couts KL, Bemis J, Turner JA, Bagby SM, Murphy D, Christiansen J, Hintzsche JD, Le A, Pitts TM, Wells K, Applegate A, Amato C, Multani P, Chow-Maneval E, Tentler JJ, Shellman YG, Rioth MJ, Tan AC, Gonzalez R, Medina T, Doebele RC, Robinson WA.

Mol Cancer Ther. 2018 Jan;17(1):222-231. doi: 10.1158/1535-7163.MCT-17-0472. Epub 2017 Oct 20.

PMID:
29054983
12.

Repigmentation of Human Vitiligo Skin by NBUVB Is Controlled by Transcription of GLI1 and Activation of the β-Catenin Pathway in the Hair Follicle Bulge Stem Cells.

Goldstein NB, Koster MI, Jones KL, Gao B, Hoaglin LG, Robinson SE, Wright MJ, Birlea SI, Luman A, Lambert KA, Shellman YG, Fujita M, Robinson WA, Roop DR, Norris DA, Birlea SA.

J Invest Dermatol. 2018 Mar;138(3):657-668. doi: 10.1016/j.jid.2017.09.040. Epub 2017 Oct 17.

PMID:
29054607
13.

Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.

Korch C, Hall EM, Dirks WG, Ewing M, Faries M, Varella-Garcia M, Robinson S, Storts D, Turner JA, Wang Y, Burnett EC, Healy L, Kniss D, Neve RM, Nims RW, Reid YA, Robinson WA, Capes-Davis A.

Int J Cancer. 2018 Feb 1;142(3):561-572. doi: 10.1002/ijc.31067. Epub 2017 Oct 10.

14.

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.

Hintzsche JD, Gorden NT, Amato CM, Kim J, Wuensch KE, Robinson SE, Applegate AJ, Couts KL, Medina TM, Wells KR, Wisell JA, McCarter MD, Box NF, Shellman YG, Gonzalez RC, Lewis KD, Tentler JJ, Tan AC, Robinson WA.

Melanoma Res. 2017 Jun;27(3):189-199. doi: 10.1097/CMR.0000000000000345.

15.

A Survey of Computational Tools to Analyze and Interpret Whole Exome Sequencing Data.

Hintzsche JD, Robinson WA, Tan AC.

Int J Genomics. 2016;2016:7983236. doi: 10.1155/2016/7983236. Epub 2016 Dec 14. Review.

16.

Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments.

Mukherjee N, Almeida A, Partyka KA, Lu Y, Schwan JV, Lambert K, Rogers M, Robinson WA, Robinson SE, Applegate AJ, Amato CM, Luo Y, Fujita M, Norris DA, Shellman YG.

Oncotarget. 2016 Dec 20;7(51):84594-84607. doi: 10.18632/oncotarget.13141.

17.

Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.

Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P.

Clin Cancer Res. 2017 Apr 1;23(7):1710-1721. doi: 10.1158/1078-0432.CCR-15-2851. Epub 2016 Oct 4.

18.

Isolating RNA from precursor and mature melanocytes from human vitiligo and normal skin using laser capture microdissection.

Goldstein NB, Koster MI, Hoaglin LG, Wright MJ, Robinson SE, Robinson WA, Roop DR, Norris DA, Birlea SA.

Exp Dermatol. 2016 Oct;25(10):805-11. doi: 10.1111/exd.13072.

19.

Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells.

Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG.

Oncotarget. 2017 Jul 18;8(29):46801-46817. doi: 10.18632/oncotarget.8695.

20.

IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.

Hintzsche J, Kim J, Yadav V, Amato C, Robinson SE, Seelenfreund E, Shellman Y, Wisell J, Applegate A, McCarter M, Box N, Tentler J, De S, Robinson WA, Tan AC.

J Am Med Inform Assoc. 2016 Jul;23(4):721-30. doi: 10.1093/jamia/ocw022. Epub 2016 Mar 28.

21.

Patterns of Occurrence of Sharks in Sydney Harbour, a Large Urbanised Estuary.

Smoothey AF, Gray CA, Kennelly SJ, Masens OJ, Peddemors VM, Robinson WA.

PLoS One. 2016 Jan 29;11(1):e0146911. doi: 10.1371/journal.pone.0146911. eCollection 2016.

22.

SASH1 Is Involved in an Autosomal Dominant Lentiginous Phenotype.

Shellman YG, Lambert KA, Brauweiler A, Fain P, Spritz RA, Martini M, Janssen KP, Box NF, Terzian T, Rewers M, Horvath A, Stratakis CA, Robinson WA, Robinson SE, Norris DA, Artinger KB, Pacheco TR.

J Invest Dermatol. 2015 Dec;135(12):3192-3194. doi: 10.1038/jid.2015.292. Epub 2015 Jul 23. No abstract available.

23.

Narrow Band Ultraviolet B Treatment for Human Vitiligo Is Associated with Proliferation, Migration, and Differentiation of Melanocyte Precursors.

Goldstein NB, Koster MI, Hoaglin LG, Spoelstra NS, Kechris KJ, Robinson SE, Robinson WA, Roop DR, Norris DA, Birlea SA.

J Invest Dermatol. 2015 Aug;135(8):2068-2076. doi: 10.1038/jid.2015.126. Epub 2015 Mar 30.

24.

Stream biomonitoring using macroinvertebrates around the globe: a comparison of large-scale programs.

Buss DF, Carlisle DM, Chon TS, Culp J, Harding JS, Keizer-Vlek HE, Robinson WA, Strachan S, Thirion C, Hughes RM.

Environ Monit Assess. 2015 Jan;187(1):4132. doi: 10.1007/s10661-014-4132-8. Epub 2014 Dec 9.

PMID:
25487459
25.

Long term storage of dry versus frozen RNA for next generation molecular studies.

Seelenfreund E, Robinson WA, Amato CM, Tan AC, Kim J, Robinson SE.

PLoS One. 2014 Nov 7;9(11):e111827. doi: 10.1371/journal.pone.0111827. eCollection 2014.

26.

Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells.

Mukherjee N, Reuland SN, Lu Y, Luo Y, Lambert K, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG.

J Invest Dermatol. 2015 Mar;135(3):842-850. doi: 10.1038/jid.2014.464. Epub 2014 Oct 28.

27.

Therapeutic monoclonal antibodies in human breast milk: a case study.

Ross E, Robinson SE, Amato C, McMillan C, Westcott J, Wolf T, Robinson WA.

Melanoma Res. 2014 Apr;24(2):177-80. doi: 10.1097/CMR.0000000000000047.

PMID:
24476799
28.

Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP-9, IL-6, TGF-β1 and EMMPRIN.

Redzic JS, Kendrick AA, Bahmed K, Dahl KD, Pearson CG, Robinson WA, Robinson SE, Graner MW, Eisenmesser EZ.

PLoS One. 2013 Aug 1;8(8):e71225. doi: 10.1371/journal.pone.0071225. Print 2013.

29.

Management of external ear melanoma: the same or something different?

Jones TS, Jones EL, Gao D, Pearlman NW, Robinson WA, McCarter M.

Am J Surg. 2013 Sep;206(3):307-13. doi: 10.1016/j.amjsurg.2012.10.038. Epub 2013 May 7.

30.

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.

Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska MJ, Le PN, Eagles-Soukup JR, Kako SL, Takimoto SM, Sehrt DB, Umpierrez A, Pittman MA, Macfadden SM, Helber RM, Peterson S, Hausman DF, Said S, Leem TH, Goddard JA, Arcaroli JJ, Messersmith WA, Robinson WA, Hirsch FR, Varella-Garcia M, Raben D, Wang XJ, Song JI, Tan AC, Jimeno A.

Mol Oncol. 2013 Aug;7(4):776-90. doi: 10.1016/j.molonc.2013.03.004. Epub 2013 Apr 4.

31.

Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result.

Jones EL, Jones TS, Pearlman NW, Gao D, Stovall R, Gajdos C, Kounalakis N, Gonzalez R, Lewis KD, Robinson WA, McCarter MD.

JAMA Surg. 2013 May;148(5):456-61. doi: 10.1001/jamasurg.2013.1335.

32.

CtBP1 is expressed in melanoma and represses the transcription of p16INK4a and Brca1.

Deng H, Liu J, Deng Y, Han G, Shellman YG, Robinson SE, Tentler JJ, Robinson WA, Norris DA, Wang XJ, Zhang Q.

J Invest Dermatol. 2013 May;133(5):1294-301. doi: 10.1038/jid.2012.487. Epub 2013 Jan 10.

33.

Sweat gland carcinoma versus metastatic breast carcinoma: a continued struggle among clinicians and dermatopathologists.

Ellis LZ, Prado R, High W, Robinson WA, Mellette JR.

J Am Acad Dermatol. 2012 Oct;67(4):e156-7. doi: 10.1016/j.jaad.2012.01.005. No abstract available.

PMID:
22980278
34.

ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.

Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, Wang J, Gonzalez R, Thompson DC, Norris DA, Roop DR, Vasiliou V, Fujita M.

Stem Cells. 2012 Oct;30(10):2100-13. doi: 10.1002/stem.1193.

35.

Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.

Luo Y, Ellis LZ, Dallaglio K, Takeda M, Robinson WA, Robinson SE, Liu W, Lewis KD, McCarter MD, Gonzalez R, Norris DA, Roop DR, Spritz RA, Ahn NG, Fujita M.

J Invest Dermatol. 2012 Oct;132(10):2440-2450. doi: 10.1038/jid.2012.161. Epub 2012 May 24.

36.

Historic and personal reflections on HCQIA. Perspectives of a former federal executive.

Robinson WA.

J Leg Med. 2012 Jan;33(1):43-61. doi: 10.1080/01947648.2012.657598. No abstract available.

PMID:
22439707
37.

Desmoid tumors in pregnant and postpartum women.

Robinson WA, McMillan C, Kendall A, Pearlman N.

Cancers (Basel). 2012 Feb 21;4(1):184-92. doi: 10.3390/cancers4010184.

38.

The RET G691S polymorphism is a germline variant in desmoplastic malignant melanoma.

Barr J, Amato CM, Robinson SE, Kounalakis N, Robinson WA.

Melanoma Res. 2012 Feb;22(1):92-5. doi: 10.1097/CMR.0b013e32834defd6.

39.

Transcriptome profiling of whole blood cells identifies PLEK2 and C1QB in human melanoma.

Luo Y, Robinson S, Fujita J, Siconolfi L, Magidson J, Edwards CK, Wassmann K, Storm K, Norris DA, Bankaitis-Davis D, Robinson WA, Fujita M.

PLoS One. 2011;6(6):e20971. doi: 10.1371/journal.pone.0020971. Epub 2011 Jun 15.

40.

Recovery of MicroRNA from Stored Human Peripheral Blood Samples.

Seelenfreund E, Robinson SE, Amato CM, Bemis LT, Robinson WA.

Biopreserv Biobank. 2011 Mar;9(1):29-33. doi: 10.1089/bio.2010.0026. Epub 2011 Mar 21.

PMID:
24850203
41.

p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation.

Terzian T, Torchia EC, Dai D, Robinson SE, Murao K, Stiegmann RA, Gonzalez V, Boyle GM, Powell MB, Pollock PM, Lozano G, Robinson WA, Roop DR, Box NF.

Pigment Cell Melanoma Res. 2010 Dec;23(6):781-94. doi: 10.1111/j.1755-148X.2010.00773.x.

42.

The anatomic distribution of melanoma and relationships with childhood nevus distribution in Colorado.

Juhl AL, Byers TE, Robinson WA, Morelli JG, Crane LA.

Melanoma Res. 2009 Aug;19(4):252-9. doi: 10.1097/CMR.0b013e32832e0b81.

43.

Increased survival from stage IV melanoma associated with fewer regulatory T Cells.

Baumgartner JM, Gonzalez R, Lewis KD, Robinson WA, Richter DA, Palmer BE, Wilson CC, McCarter MD.

J Surg Res. 2009 Jun 1;154(1):13-20. doi: 10.1016/j.jss.2008.04.043. Epub 2008 Jun 2.

PMID:
19062042
44.

Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature review.

Amaria RN, Corboy JR, Finlayson CA, Robinson WA, Borges VF.

Clin Breast Cancer. 2008 Oct;8(5):449-52. doi: 10.3816/CBC.2008.n.055.

PMID:
18952560
45.

Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma.

Chen RW, Bemis LT, Amato CM, Myint H, Tran H, Birks DK, Eckhardt SG, Robinson WA.

Blood. 2008 Aug 1;112(3):822-9. doi: 10.1182/blood-2008-03-142182. Epub 2008 May 15.

46.

Gastrointestinal melanoma or clear cell sarcoma? Molecular evaluation of 7 cases previously diagnosed as malignant melanoma.

Lyle PL, Amato CM, Fitzpatrick JE, Robinson WA.

Am J Surg Pathol. 2008 Jun;32(6):858-66. doi: 10.1097/PAS.0b013e31815b8288.

PMID:
18408594
47.

MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines.

Bemis LT, Chen R, Amato CM, Classen EH, Robinson SE, Coffey DG, Erickson PF, Shellman YG, Robinson WA.

Cancer Res. 2008 Mar 1;68(5):1362-8. doi: 10.1158/0008-5472.CAN-07-2912.

48.

EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.

Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA Jr, Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA.

Ann Oncol. 2008 Jun;19(6):1053-9. doi: 10.1093/annonc/mdn006. Epub 2008 Feb 27.

PMID:
18304967
49.

Platelet-derived growth factor receptor alpha mutational status and immunohistochemical expression in Merkel cell carcinoma: implications for treatment with imatinib mesylate.

Swick BL, Ravdel L, Fitzpatrick JE, Robinson WA.

J Cutan Pathol. 2008 Feb;35(2):197-202. doi: 10.1111/j.1600-0560.2007.00793.x.

PMID:
18190445
50.

Genetic mutations involved in melanoma: a summary of our current understanding.

High WA, Robinson WA.

Adv Dermatol. 2007;23:61-79. Review.

PMID:
18159896

Supplemental Content

Loading ...
Support Center